Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Interest & Investment Income (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Interest & Investment Income for 13 consecutive years, with $12.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 31.11% year-over-year to $12.4 million, compared with a TTM value of $56.4 million through Dec 2025, up 17.25%, and an annual FY2025 reading of $56.4 million, up 17.25% over the prior year.
  • Interest & Investment Income was $12.4 million for Q4 2025 at Agios Pharmaceuticals, down from $13.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $18.0 million in Q4 2024 and bottomed at -$92000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $7.6 million, with a median of $8.2 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income crashed 105.2% in 2021, then soared 2048.91% in 2022.
  • Year by year, Interest & Investment Income stood at $332000.0 in 2021, then soared by 1854.22% to $6.5 million in 2022, then soared by 32.92% to $8.6 million in 2023, then soared by 108.89% to $18.0 million in 2024, then plummeted by 31.11% to $12.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for AGIO at $12.4 million in Q4 2025, $13.4 million in Q3 2025, and $14.5 million in Q2 2025.